Search

Your search keyword '"Tanabe Makito"' showing total 44 results
Start Over Author "Tanabe Makito" Search Limiters Available in Library Collection
44 results on '"Tanabe Makito"'

3. Association Between Acute Fall in Estimated Glomerular Filtration Rate After Treatment for Primary Aldosteronism and Long-Term Decline in Renal Function

Author

Kobayashi, Hiroki, Abe, Masanori, Nakamura, Yoshihiro, Takahashi, Katsutoshi, Fujita, Megumi, Takeda, Yoshiyu, Yoneda, Takashi, Kurihara, Isao, Itoh, Hiroshi, Tsuiki, Mika, Wada, Norio, Ichijo, Takamasa, Katabami, Takuyuki, Ogawa, Yoshihiro, Kawashima, Junji, Yoshimoto, Takanobu, Sone, Masakatsu, Inagaki, Nobuya, Watanabe, Minemori, Kamemura, Kohei, Matsuda, Yuichi, Izawa, Shoichiro, Tanabe, Makito, Tanabe, Akiyo, Suzuki, Tomoko, and Naruse, Mitsuhide

Published
2019
Full Text
View/download PDF

10. Activation of overexpressed glucagon‐like peptide‐1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression

Author

Shigeoka, Toru, primary, Nomiyama, Takashi, additional, Kawanami, Takako, additional, Hamaguchi, Yuriko, additional, Horikawa, Tsuyoshi, additional, Tanaka, Tomoko, additional, Irie, Shinichiro, additional, Motonaga, Ryoko, additional, Hamanoue, Nobuya, additional, Tanabe, Makito, additional, Nabeshima, Kazuki, additional, Tanaka, Masatoshi, additional, Yanase, Toshihiko, additional, and Kawanami, Daiji, additional

Published
2020
Full Text
View/download PDF

12. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation

Author

Komatsu, Shiho, primary, Nomiyama, Takashi, additional, Numata, Tomohiro, additional, Kawanami, Takako, additional, Hamaguchi, Yuriko, additional, Iwaya, Chikayo, additional, Horikawa, Tsuyoshi, additional, Fujimura-Tanaka, Yuki, additional, Hamanoue, Nobuya, additional, Motonaga, Ryoko, additional, Tanabe, Makito, additional, Inoue, Ryuji, additional, Yanase, Toshihiko, additional, and Kawanami, Daiji, additional

Published
2020
Full Text
View/download PDF

14. 頭蓋咽頭腫の長期治療経過に伴う汎下垂体機能低下症により肝硬変症をきたしたと考えられる一例

Author

Terawaki, Yuichi, Murase, Kunitaka, Motonaga, Ryoko, Tanabe, Makito, Nomiyama, Takashi, Shakado, Satoshi, Mizoguchi, Mikiro, Sakisaka, Shotaro, and Yanase, Toshihiko

Subjects
Craniopharyngioma, 肝硬変, 非アルコール性脂肪性肝炎, Liver cirrhosis, Growth hormone deficiency, Panhypopituitarism, 汎下垂体機能低下症, Non-alcoholic stetohepatitis, 非アルコール性脂肪性肝疾患, 成長ホルモン欠乏症, 頭蓋咽頭腫, Non-alcoholic fatty liver disease
Abstract

A 38-year-old man diagnosed with craniopharyngioma at 8 years old underwent repeated surgery and radiation therapy. Complications included panhypopituitarism including growth hormone deficiency and hypogonadism at 13 years old. At 26 years of age, a slight fatty liver was found, which finally developed into liver cirrhosis (LC) at 35 years old. Viral infection or other etiologies causing LC were negative on serum examinations. Liver biopsy suggested a possibility of burn-out non-alcoholic steatohepatitis. This case indicates that a long-standing growth hormone deficiency and hypogonadism may lead to LC as a type of burn-out non-alcoholic steatohepatitis., 症例は38歳男性．8歳時に頭蓋咽頭腫と診断され，手術及び放射線療法がおこなわれた．その後も再発を繰り返し，13歳時には成長ホルモン分泌不全症及び性腺機能低下症を伴う汎下垂体機能低下症を認めた．26歳時に軽度の脂肪肝を指摘され，35歳時には肝硬変に至った．肝硬変を引き起こすようなウイルス性やその他の肝疾患は血液検査などから否定的であり，肝生検の結果はburn-out NASHが疑われた．本症例の長期経過から，汎下垂体機能低下症に伴う長期のGH分泌不全症に起因するNASHがその原因と推定された．

Published
2016

15. Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

Author

Takahashi, Hiroyuki, primary, Nomiyama, Takashi, additional, Terawaki, Yuichi, additional, Horikawa, Takeshi, additional, Kawanami, Takako, additional, Hamaguchi, Yuriko, additional, Tanaka, Tomoko, additional, Motonaga, Ryoko, additional, Fukuda, Takashi, additional, Tanabe, Makito, additional, and Yanase, Toshihiko, additional

Published
2019
Full Text
View/download PDF

16. SAT-369 Proposal of Optimal Cutoff value for Serum Cortisol after an Overnight 1-mg Dexamethasone Suppression Test - Results from Multicenter Collaborative Research in Japan.

Author

Tanabe, Makito, primary, Oki, Yutaka, additional, Katabami, Takuyuki, additional, Otsuki, Michio, additional, Kageyama, Kazunori, additional, Tanaka, Tomoaki, additional, Kawate, Hisaya, additional, Doi, Masaru, additional, Akehi, Yuko, additional, Ichijo, Takamasa, additional, and Yanase, Toshihiko, additional

Published
2019
Full Text
View/download PDF

20. Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).

Author

Terawaki, Yuichi, Iwaya, Chikayo, Nomiyama, Takashi, Shimono, Dai, Horikawa, Tsuyoshi, Fujimura-Tanaka, Yuki, Shigeoka, Toru, Hamanoue, Nobuya, Motonaga, Ryoko, Tanabe, Makito, Yanase, Toshihiko, and Kawanami, Daiji

Abstract

Dipeptidyl peptidase-4 inhibitors (DPP-4Is) are one of the most frequently prescribed anti-diabetic agents in Japan, and they are often used in combination with insulin secretagogues, such as sulfonylureas and glinides. In the present study, we determined the efficacy and safety of the use of repaglinide or glimepiride, a sulfonylurea, in combination with a DPP-4I, in Japanese patients with type 2 diabetes mellitus (T2DM). This study was an investigator-initiated, open-label, randomized, multi-center prospective study. Patients with T2DM, which was inadequately controlled using a DPP-4I, were randomized to a repaglinide group or a glimepiride group and treated for 48 weeks. The primary outcomes were the reductions in glycated hemoglobin (HbA1c) and glucose oscillation, identified using continuous glucose monitoring, after 12 weeks. The secondary outcome was the change in carotid intima-media thickness (IMT), measured by ultrasonography, after 48 weeks. A total of 61 patients were recruited and analyzed in the study. Twelve weeks of treatment with 1.5 mg repaglinide or 1 mg glimepiride significantly reduced HbA1c, and a larger reduction in HbA1c occurred in the repaglinide group than the glimepiride group. Mean subcutaneous glucose concentration was significantly reduced in both groups, but the glucose oscillation did not decrease. Interestingly, the mean left IMT significantly increased in the glimepiride group, but not in the repaglinide group. More hypoglycemic events were observed in the glimepiride group. These data suggest that repaglinide reduces HbA1c more effectively than glimepiride when used in combination with a DPP-4I, and causes fewer hypoglycemic events. Trail registry: This study is registered with UMIN-CTR (UMIN000018321). [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

21. HMGA1a Induces Alternative Splicing of the Estrogen Receptor-αlpha Gene by Trapping U1 snRNP to an Upstream Pseudo-5′ Splice Site

Author

Ohe, Kenji, primary, Miyajima, Shinsuke, additional, Tanaka, Tomoko, additional, Hamaguchi, Yuriko, additional, Harada, Yoshihiro, additional, Horita, Yuta, additional, Beppu, Yuki, additional, Ito, Fumiaki, additional, Yamasaki, Takafumi, additional, Terai, Hiroki, additional, Mori, Masayoshi, additional, Murata, Yusuke, additional, Tanabe, Makito, additional, Abe, Ichiro, additional, Ashida, Kenji, additional, Kobayashi, Kunihisa, additional, Enjoji, Munechika, additional, Nomiyama, Takashi, additional, Yanase, Toshihiko, additional, Harada, Nobuhiro, additional, Utsumi, Toshiaki, additional, and Mayeda, Akila, additional

Published
2018
Full Text
View/download PDF

27. Diagnosis and treatment of adrenal insufficiency including adrenal crisis: a Japan Endocrine Society clinical practice guideline [Opinion]

Author

Yanase, Toshihiko, primary, Tajima, Toshihiro, additional, Katabami, Takuyuki, additional, Iwasaki, Yasumasa, additional, Tanahashi, Yusuke, additional, Sugawara, Akira, additional, Hasegawa, Tomonobu, additional, Mune, Tomoatsu, additional, Oki, Yutaka, additional, Nakagawa, Yuichi, additional, Miyamura, Nobuhiro, additional, Shimizu, Chikara, additional, Otsuki, Michio, additional, Nomura, Masatoshi, additional, Akehi, Yuko, additional, Tanabe, Makito, additional, and Kasayama, Soji, additional

Published
2016
Full Text
View/download PDF

30. Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis

Author

Terawaki, Yuichi, primary, Nomiyama, Takashi, additional, Takahashi, Hiroyuki, additional, Tsutsumi, Yoko, additional, Murase, Kunitaka, additional, Nagaishi, Ryoko, additional, Tanabe, Makito, additional, Kudo, Tadachika, additional, Kobayashi, Kunihisa, additional, Yasuno, Tetsuhiko, additional, Nakashima, Hitoshi, additional, and Yanase, Toshihiko, additional

Published
2015
Full Text
View/download PDF

32. Relationship between Distant Metastases and Cervical Lymph Node Metastases in Patients with Papillary Carcinoma of Thyroid

Author

Hattori Naoki, Hino Megumi, Hirono Yoshinobu, Kurahachi Hiroyuki, Funabiki Kazuo, Ikekubo Katsuji, Inada Yuki, Tanabe Makito, Koh Toshikiyo, Ohmura Masaki, Mizukami Chikashi, Ishihara Takashi, Isono Michio, and Yamamoto Etsuo

Subjects
Total thyroidectomy, Pathology, medicine.medical_specialty, business.industry, Thyroid, Distant metastasis, Follicular carcinoma, medicine.anatomical_structure, Otorhinolaryngology, Cervical lymph nodes, medicine, In patient, Papillary carcinoma, business, Lymph node
Abstract

In a series of 43 patients with differentiated carcinomas of the thyroid who were treated with total thyroidectomy during the past 2 years in Kobe City General Hospital, 5 with papillary carcinoma and 1 with follicular carcinoma had distant metastases. There was no particular relationship between the distant metastasis and the number of metastatic cervical lymph nodes. On the other hand, the number of metastases was high in the jugular chain in patients with distant metastases. Therefore, total thyroidectomy is recommended in patients with jugular chain metastases.

Published
1991

33. Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database.

Author

Tanabe, Makito, Motonaga, Ryoko, Terawaki, Yuichi, Nomiyama, Takashi, and Yanase, Toshihiko

Subjects
*HYPOGLYCEMIC agents, *PEOPLE with diabetes, *BIGUANIDE, *CARDIOVASCULAR diseases, HOSPITAL information systems
Abstract

Aims/Introduction In treatment algorithms of type 2 diabetes mellitus in Western countries, biguanides are recommended as first-line agents. In Japan, various oral hypoglycemic agents ( OHAs) are available, but prescription patterns are unclear. Materials and Methods Data of 7,108 and 2,655 type 2 diabetes mellitus patients in study 1 and study 2, respectively, were extracted from the Medical Data Vision database (2008-2013). Cardiovascular disease history was not considered in study 1, but was in study 2. Initial choice of OHA, adherence to its use, effect on glycated hemoglobin levels for 2 years and the second choice of OHA were investigated. Results In study 1, α-glucosidase inhibitor, glinide and thiazolidinedione were preferentially medicated in relatively lower glycated hemoglobin cases compared with other OHAs. The two most prevalent first prescriptions of OHAs were biguanides and dipeptidyl peptidase-4 inhibitors, and the greatest adherence was for α-glucosidase inhibitors. In patients treated continuously with a single OHA for 2 years, improvement in glycated hemoglobin levels was greatest for dipeptidyl peptidase-4 inhibitors. As a second OHA added to the first OHA during the first 2 years, dipeptidyl peptidase-4 inhibitors were chosen most often, especially if a biguanide was the first OHA. In study 2, targeting patients with a cardiovascular disease history, a similar tendency to study 1 was observed in the first choice of OHA, adherence and the second choice of OHA. Conclusions Even in Japanese type 2 diabetes mellitus patients, a Western algorithm seems to be respected to some degree. The OHA choice does not seem to be affected by a cardiovascular disease history. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

35. Long-term study of subclinical Cushing^|^rsquo;s syndrome shows high prevalence of extra-adrenal malignancy in patients with functioning bilateral adrenal tumors

Author

Kawate, Hisaya, primary, Kohno, Michiko, additional, Matsuda, Yayoi, additional, Akehi, Yuko, additional, Tanabe, Makito, additional, Horiuchi, Toshihiro, additional, Ohnaka, Keizo, additional, Nomura, Masatoshi, additional, Yanase, Toshihiko, additional, and Takayanagi, Ryoichi, additional

Published
2014
Full Text
View/download PDF

37. Short-Term Effects of β-adrenergic Antagonists and Methimazole in New-Onset Thyrotoxicosis Caused by Graves' Disease

Author

Tagami, Tetsuya, primary, Yambe, Yuko, additional, Tanaka, Tsuyoshi, additional, Tanaka, Takashi, additional, Ogo, Atsushi, additional, Yoshizumi, Hideyuki, additional, Kaise, Kazuo, additional, Higashi, Kiichiro, additional, Tanabe, Makito, additional, Shimazu, Satoko, additional, Usui, Takeshi, additional, Shimatsu, Akira, additional, and Naruse, Mitsuhide, additional

Published
2012
Full Text
View/download PDF

38. Urinary Cystatin C as a Potential Risk Marker for Cardiovascular Disease and Chronic Kidney Disease in Patients with Obesity and Metabolic Syndrome

Author

Satoh-Asahara, Noriko, primary, Suganami, Takayoshi, additional, Majima, Takafumi, additional, Kotani, Kazuhiko, additional, Kato, Yasuhisa, additional, Araki, Rika, additional, Koyama, Kazunori, additional, Okajima, Taiichiro, additional, Tanabe, Makito, additional, Oishi, Mariko, additional, Himeno, Akihiro, additional, Kono, Shigeo, additional, Sugawara, Akira, additional, Hattori, Masakazu, additional, Ogawa, Yoshihiro, additional, and Shimatsu, Akira, additional

Published
2011
Full Text
View/download PDF

43. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).

Author

Nomiyama T, Shimono D, Horikawa T, Fujimura Y, Ohsako T, Terawaki Y, Fukuda T, Motonaga R, Tanabe M, and Yanase T

Subjects
Adiponectin blood, Adult, Aged, Blood Glucose, Body Mass Index, C-Peptide blood, Diabetes Mellitus, Type 2 blood, Female, Glucosides adverse effects, Humans, Hypoglycemic Agents adverse effects, Male, Middle Aged, Prospective Studies, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Thiophenes adverse effects, Treatment Outcome, Young Adult, Diabetes Mellitus, Type 2 drug therapy, Glucosides therapeutic use, Hypoglycemic Agents therapeutic use, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Thiophenes therapeutic use
Abstract

Sodium-glucose co-transporter-2 inhibitors are newly established anti-diabetic agents with a unique glucose-lowering mechanism. In the present study, we investigated the efficacy and safety of the sodium-glucose co-transporter-2 inhibitor ipragliflozin (Ipra) for metabolic markers and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus (T2DM). This study was an investigator-initiated, open-label, single-arm, multicenter prospective study. Patients with T2DM were treated with 50 mg Ipra for 24 and 52 weeks. The primary outcome investigated was the reduction of glycated hemoglobin (HbA1c) level. The secondary outcome was the change in other metabolic and cardiovascular parameters by 24 weeks. Before and after 52 weeks of treatment, carotid intima-media thickening (IMT) was measured by echography. A total of 134 patients were recruited in the study. A 24-week treatment with 50 mg Ipra daily significantly reduced HbA1c level (-0.6%, p < 0.01). Body mass index (BMI), blood pressure and serum C-peptide were reduced significantly (p < 0.05), while serum glucagon level was unchanged. Interestingly, the serum adiponectin and high-density lipoprotein (HDL) cholesterol levels were significantly increased by Ipra. However, 52 weeks of Ipra treatment did not change carotid IMT. Multiple regression analysis revealed that the only significant contributing factor for HbA1c reduction by Ipra was baseline HbA1c level. These data suggest that Ipra decreased not only glucose level but also BMI, blood pressure and serum C-peptide, and the contributing factor for HbA1c reduction by Ipra was baseline HbA1c level. Further, Ipra improved serum adiponectin and HDL cholesterol levels.

Published
2018
Full Text
View/download PDF

44. HMGA1a Induces Alternative Splicing of the Estrogen Receptor- α lpha Gene by Trapping U1 snRNP to an Upstream Pseudo-5' Splice Site.

Author

Ohe K, Miyajima S, Tanaka T, Hamaguchi Y, Harada Y, Horita Y, Beppu Y, Ito F, Yamasaki T, Terai H, Mori M, Murata Y, Tanabe M, Abe I, Ashida K, Kobayashi K, Enjoji M, Nomiyama T, Yanase T, Harada N, Utsumi T, and Mayeda A

Abstract

Objectives: The high-mobility group A protein 1a (HMGA1a) protein is known as a transcription factor that binds to DNA, but recent studies have shown it exerts novel functions through RNA-binding. We were prompted to decipher the mechanism of HMGA1a-induced alternative splicing of the estrogen receptor alpha (ERα) that we recently reported would alter tamoxifen sensitivity in MCF-7 TAMR1 cells. Methods: Endogenous expression of full length ERα66 and its isoform ERα46 were evaluated in MCF-7 breast cancer cells by transient expression of HMGA1a and an RNA decoy (2'-O-methylated RNA of the HMGA1a RNA-binding site) that binds to HMGA1a. RNA-binding of HMGA1a was checked by RNA-EMSA . In vitro splicing assay was performed to check the direct involvement of HMGA1a in splicing regulation. RNA-EMSA assay in the presence of purified U1 snRNP was performed with psoralen UV crosslinking to check complex formation of HMGA1a-U1 snRNP at the upstream pseudo-5' splice site of exon 1. Results: HMGA1a induced exon skipping of a shortened exon 1 of ERα in in vitro splicing assays that was blocked by the HMGA1a RNA decoy and sequence-specific RNA-binding was confirmed by RNA-EMSA. RNA-EMSA combined with psoralen UV crosslinking showed that HMGA1a trapped purified U1 snRNP at the upstream pseudo-5' splice site. Conclusions: Regulation of ERα alternative splicing by an HMGA1a-trapped U1 snRNP complex at the upstream 5' splice site of exon 1 offers novel insight on 5' splice site regulation by U1 snRNP as well as a promising target in breast cancer therapy where alternative splicing of ERα is involved.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results